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Influenza virus infects millions of people every year worldwide, with elderly and very young people among the
most critically affected. Strains that constitute a pandemic threat are characterized by the severity of the clinical
manifestations and mortality rates and tend to require the urgent production of hundreds of millions of vaccine
doses in very short periods of time. There is an evident need to develop new generations of influenza vaccines
based on robust production systems such as mammalian or insect cell cultures. These systems may allow, in
contrast to production in embryonated chicken eggs, a faster response capacity, a superior manufacturing
process control and a more reliable and better characterized product.
In this work, we have used influenza strains that constitute a potential pandemic threat (H1N1, H3N2 and H7N9
subtypes) for the development and evaluation of a vaccine production process in HEK293SF cells. The analysis
of culture parameters was conducted in parallel using the A/PR/8/34 (H1N1) and the A/Hong-Kong/8/68 (H3N2)
strains plus one H7N9 subtype reassortant. The reassortant virus carrying the HA and NA genes of the
A/Anhui/1/2013 strain on a PR8 backbone was obtained and amplified in HEK293SF cells using an 8 plasmidbased reverse genetics technique followed by an adaptation step in HEK293SF. HycellTransFx-H and Xell HEKGM serum-free media were evaluated for virus production in shake flask experiments. A range of culture
parameters was evaluated in batch including different cell densities at infection; infection at different MOI;
temperature shift at the time of infection and trypsin addition to the medium at different concentrations. Process
intensification using fed-batch and perfusion culture modes were also evaluated.
Virus yields obtained in batch with HEK-GM medium were more than one log lower than those obtained with
HycellTransFx-H. Also, the implementation of a fed-batch mode was able to overcome medium limitation at
higher cell densities. Perfusion was a more effective strategy allowing a final virus yield increment of about 2
logs. Culture conditions were scaled-up and ten controlled batch and fed-batch bioreactor runs (1-3 liters) were
completed using HycellTransFx-H, aiming to gain deeper insights into requirements for a robust upstream
bioprocess, generate material for downstream development and optimize analytical techniques for virus
particles quantification. On-line monitoring and reproducibility of the production kinetics was also followed in the
3L runs by capacitance measurements. Median Tissue Culture Infectious Dose (TCID50)/mL in the range of 109
IVP/ml was obtained for the H1N1 strain while values over 107 and 8 x 107 IVP/ml were achieved for the H7N9
and H3N2 subtypes, respectively. The quantification methods used comprised TCID50/mL (IVP/per mL), viral
genomes quantified by ddPCR (copies/ml), hemagglutination (HA units/ml) and neuraminidase (NA units/ml)
assays, as well as dot blot and SRID (both ug of HA/ml).
In summary, this work is a further step providing solid bases for the completion of a scalable and robust
manufacturing process for a multivalent influenza vaccine in HEK293SF cells, process that might be activated
and scaled-out in response to influenza pandemic situation.
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